Skip to main content
Premium Trial:

Request an Annual Quote

White Papers and Videos

Digging Deeper into OncoSpan’s NGS Data

White Paper

This application note from Horizon Discovery describes the types of data included in the high-coverage batch-specific in silico NGS data sets that accompany OncoSpan oncology reference standards as well as how the data are generated and validated.

Developing a High-Coverage, Pan-Cancer NGS Reference Material for Assay Validation

White Paper

Comprehensive genetic testing using large gene NGS panels is used commonly in the detection of somatic variants in cancer genetic analysis. Errors introduced during each step of the workflow can limit the interpretation of results.

This poster from Horizon Discovery describes the development of a family of oncology reference materials made to closely mimic patient samples, validate end-to-end processes from extraction to analysis, and determine limit of detection in order to ensure the reliability of NGS workflows and mitigate internal biases.

Pan-Cancer Six-Fusion Panel FFPE RNA (HD834) Reference Standard

White Paper

This application note from Horizon Discovery describes the importance of novel kinase fusion detection across cancer types, the challenges of detecting fusions with FISH and targeted RT-qPCR, the advantages of RNA profiling, and Horizon’s FFPE control material, containing 6 clinically relevant, cell-line derived, kinase-fusion RNA biomarkers.

Horizon Shines in Extensive FINH Study Identifying Validated Quality Control Materials as Vital Components of ctDNA Assay Workflows

White Paper

This white paper from Horizon Discovery summarizes the findings of a Foundation for the National Institutes of Health study investigating the performance of quality control materials (QCMs) in circulating tumor DNA (ctDNA) assays, demonstrating how a laboratory’s ctDNA assay workflow can be affected by the source of their QCMs.

Discover Novel Predictive Biomarkers with GeoMx Digital Spatial Profiler (DSP)

White Paper

Predictive biomarkers help to identify tumors that are most likely to benefit from a specific treatment and spare patients from toxic effects of ineffective therapies. Both genetic mutations and protein levels in diseased tissues are examples of predictive biomarkers, yet few platforms enable the simultaneous evaluation of both RNA and protein.

The GeoMx Digital Spatial Profiler (DSP) from NanoString provides morphological context in spatial transcriptomics and spatial proteomics experiments for immuno-oncology research. The GeoMx DSP platform can investigate novel biomarkers in tissue samples because it offers digital profiling of protein and RNA analytes on the same slide.

This application note from Canopy Biosciences, a Center of Excellence for NanoString services, outlines a recent study that used the GeoMx DSP to investigate novel biomarkers associated with beneficial PD-1 therapy in formalin-fixed, paraffin-embedded samples from patients with non-small cell lung cancer.

Mass Spectrometry Imaging: Top 8 Benefits in Oncology Drug Discovery and Development

White Paper

An important part of preclinical research and early-phase drug development is determining a drug’s biological distribution and its metabolites to establish the pharmacokinetic-pharmacodynamic relationship and potential toxicity. This infographic from Pyxant Labs shows how mass spectrometry imaging offers a precise and detailed look into each of these elements and can be an invaluable tool for improving the body of scientific evidence available to justify the advancement of oncology drugs into human trials.

Real-World PD-L1 Testing Data Provides Insight into the Evolving Immuno-oncology Landscape

White Paper

This white paper from NeoGenomics presents results from an analysis of real-world data investigating the trends in immunotherapy use, revealing insights as to the most commonly ordered biomarker tests, the complex companion diagnostics landscape, and patient outcomes.

Using Real-World Lab Data Insights to Improve Biomarker Testing in Lung Cancer

White Paper

The medical community’s understanding of lung cancer has become increasingly sophisticated in recent years and, as a result, significant advancements have been seen in targeted therapies for this patient population.

Professional organizations such as the National Comprehensive Cancer Network (NCCN) have remained at the forefront of testing and treatment paradigms based on the latest available data and drug approvals. Guidelines from NCCN for non-small cell lung cancer (NSCLC) are among the most frequently updated, with seven revisions in 2021 alone. While this speaks to the speed of the evolving landscape, it can also create proverbial whiplash among providers of lung cancer patients as they navigate the multitude of testing and treating options available to them.

This white paper from NeoGenomics compares lung cancer biomarker testing rates in the community practice setting with NCCN guidelines, discussing the implications of current testing algorithms on time-to-treatment and tissue availability and how real-world lab data provides evidence-based rationale for building precision oncology programs.

Overcome the Four Common Data Challenges in Clinical Diagnostics

White Paper

This white paper from Qiagen describes four challenges in scaling NGS test volume —managing high volumes of sequencing data, keeping up with the regulatory landscape, reducing operational costs, and developing and delivering tests quickly — and describes solutions employing the DNAnexus data analysis platform and Qiagen Digital Insights knowledge base.

Optimizing Results from Nucleic Acid Isolation

White Paper

This ebook from Cytiva includes articles on optimizing nucleic acid isolation, avoiding bottlenecks in high-throughput NGS sample prep, isolating nucleic acids from clinical samples, moving from column to bead-based DNA isolation, and detecting mutations with liquid biopsies in cancer diagnostics.

Investigating Cell-Free DNA in Liquid Biopsy

White Paper

Liquid biopsy is a revolutionary approach that is opening previously unexpected opportunities in oncology. It empowers the detection and isolation of circulating tumor cells, cell-free DNA, and circulating tumor DNA, drawing on the strength of NGS technologies now available. Many difficulties have been overcome, but there is still no standardized approach for liquid biopsy processing and cell-free DNA analysis. Substantial progress has been made regarding sample preparation and isolation. However, continued progress in reducing genomic DNA contamination and PCR inhibitors is needed to further improve sensitivity.

This white paper from Cytiva discusses the challenges and opportunities in measuring the small amount of cell-free DNA in liquid samples for applications including oncology, organ and transplant medicine, and non-invasive prenatal testing.

Personalized Therapy Selection: Investigation of Multiple Immune-Checkpoints

White Paper

PD1 blockade through monoclonal antibody-based therapy has revolutionized the immunotherapeutic approach against solid tumors. However, only a small number of patients benefit from this treatment due to the lack of accurate methodology such as immunohistochemistry to guide patients that could respond to this immune checkpoint inhibitor therapy. Understanding the tumor microenvironment complexity with a single biomarker is not accurate enough to predict the interaction of the drug in its site of action.

This white paper from Pyxant Labs presents a strategy in which the tumor microenvironment is deeply investigated to guide the patient efficiently toward single immune therapy or combination therapies, highlighting the relevance of simultaneously investigating multiple biomarkers to obtain an accurate picture of the immune contexture.

Proteomics at the Heart of Multiomics Studies

White Paper

Achieving the goal of precision medicine and more targeted therapeutics will require the use of systems biology approaches to understand the molecular mechanisms at work within the human body. This trend is already apparent in scientific research, with more scientists beginning to use multiomics studies to better understand diseases and to help develop the drugs needed to treat them. To this end, the integration of data from high-throughput proteomics technologies is essential, as proteins best represent individual phenotypes and the effects of environmental and lifestyle factors. In other words, proteins best reflect real-time biology, which is key in developing precision medicine.

This e-book from Olink discusses the integration of proteomics data in multiomics, focusing on how combining genetic data with proteomics help researchers identify proteins that cause disease, how proteomics adds value to multiomics studies on complex diseases, and the future of proteomics in multiomics research.

How Co-Occurring Oncogenic Mutations Impact Clinical Outcomes

White Paper

This white paper from Qiagen discusses use cases for employing QCI Interpret for Oncology clinical decision support software to annotate and interpret co-mutations, genomic changes in associated pathways that may elicit complementary effects and may provide prognostic and predictive value.

Tracking the Progress of ERBB2-Targeted Therapies from Early Case Studies to Market with COSMIC Actionability

White Paper

This white paper from Qiagen describes tracking ERBB2-targeted therapies using COSMIC Actionability, a feature within the Catalogue of Somatic Mutations in Cancer that indicates the availability of drugs that target mutations in cancer and tracks the progress of clinical studies towards making new drugs available.